Past accomplishments of our group

Set up prime-boost genetic vaccine Platform
Tumor stroma antigen identified and validated
Development of high efficacious monoclonal antibodies
More than 50 papers published in the field
IP protection for antigens, more immunogenic fusions and vectors
Candidate vaccines advanced to phase1 trials
Successful collaborations with Biotech Companies
Network with several clinical groups in Italy and outside

Takis Leadership

TAKIS LEADERSHIP
PAST ACCOMPLISHMENTSOF OUR GROUP
PAPERS

Follow Us on Linkedin

Takis is a biotech dedicated to cancer research. Our primary objective is the development of innovative therapies based on the principle that our immune system can be “instructed” to recognize the tumor and reject it as a foreign entity.

Visit our page

Terms of use
Privacy
Ethical code
This email address is being protected from spambots. You need JavaScript enabled to view it.
Webmail